Now I'll deliver all three complete documents.
MATCH-Pain: Complete Trial Package
Below are the three deliverables: (I) Statistical Analysis Plan, (II) ClinicalTrials.gov Registration Protocol, and (III) NIH R21 Grant Application Framework.
I. Statistical Analysis Plan (SAP)
1. Preamble
Trial title: Psychological Mechanism-Matched Treatment Versus Guideline-Concordant Usual Care for Chronic Low Back Pain: A Pragmatic Stratified Randomized Trial (MATCH-Pain)
SAP version: 1.0
Date: To be finalized before database lock
Prepared in accordance with: ICH E9 Statistical Principles for Clinical Trials, CONSORT-PRO extension, and the SPIRIT-Outcomes 2022 guidance
2. Study Design Summary
Pragmatic, assessor-blinded, two-arm, parallel-group, stratified randomized controlled trial. N = 150 (75 per arm). Patients with chronic non-specific LBP are phenotyped at baseline on four psychological/neurophysiological dimensions and randomized 1:1 to mechanism-matched treatment or guideline-concordant usual care.
3. Analysis Populations
| Population | Definition | Used For |
|---|
| Intention-to-treat (ITT) | All randomized participants, analyzed as allocated regardless of adherence | Primary analysis |
| Modified ITT (mITT) | All randomized participants who completed ≥1 treatment session (matched arm) or ≥1 post-baseline assessment (UC arm) | Sensitivity analysis |
| Per-protocol (PP) | Matched arm: completed ≥4 of 6 sessions + all key assessments. UC arm: remained in study through 12-wk endpoint | Sensitivity analysis |
| Safety | All randomized participants who received any study-related care | Adverse event reporting |
4. Primary Outcome Analysis
4.1 Primary Endpoint
BPI-SF interference subscale (mean of 7 items; range 0–10) at 12 weeks post-randomization.
4.2 Primary Analysis Method
Analysis of covariance (ANCOVA):
6.2 Responder Analysis
- 30% responder: Proportion achieving ≥30% reduction in BPI-SF interference from baseline
- 50% responder: Proportion achieving ≥50% reduction (substantial clinical benefit per IMMPACT)
- Compared between arms using chi-square; NNT with 95% CI calculated
6.3 Process Outcome: Phenotype Score Change
Paired within-group analysis of change in dominant phenotype score (e.g., PCS Δ for catastrophizers) at 6 and 12 weeks. Between-group comparison of phenotype score trajectories using mixed-effects models.
6.4 Cost-Effectiveness (Exploratory)
Incremental cost-effectiveness ratio (ICER) using EQ-5D-5L-derived QALYs. Healthcare resource use collected via patient log. Reported as cost per QALY gained from a societal perspective.
7. Multiplicity Control Strategy
- Primary outcome: Single test, no adjustment needed (α = 0.05, two-sided)
- Key secondary outcomes (NRS, ODI, EQ-5D-5L): Hochberg step-up procedure within this family (controls FWER at 0.05)
- Other secondary and exploratory outcomes: Reported with nominal 95% CIs; no formal multiplicity adjustment. Interpreted descriptively.
8. Interim Analysis
None planned. Sample size (N=150) and trial duration (24 months) do not justify an interim look. A Data Safety Monitoring Board (DSMB) will review blinded safety data every 6 months.
9. Software
All analyses in R (version ≥ 4.3) using packages lme4, mice, emmeans, survival, ggplot2. SAP will be time-stamped and posted on the trial registry before unblinding.
II. ClinicalTrials.gov Registration Protocol
Protocol Registration (structured per ClinicalTrials.gov PRS fields)
Identification
| Field | Entry |
|---|
| Brief title | MATCH-Pain: Mechanism-Matched Treatment for Chronic Low Back Pain |
| Official title | Psychological Mechanism-Matched Treatment Versus Guideline-Concordant Usual Care for Chronic Low Back Pain: A Pragmatic Stratified Randomized Trial |
| Acronym | MATCH-Pain |
| Secondary IDs | [IRB number TBD]; [Grant number TBD] |
Status
| Field | Entry |
|---|
| Overall status | Not yet recruiting |
| Study start date (anticipated) | [Month 1 of funding] |
| Primary completion date | [Month 21] (date of final 12-week primary endpoint collection) |
| Study completion date | [Month 24] (date of final 24-week follow-up) |
Sponsor & Collaborators
| Field | Entry |
|---|
| Sponsor | [PI's institution] |
| Responsible party | [PI name], [title], [institution] |
| Collaborators | [List departments/sites] |
Oversight
| Field | Entry |
|---|
| FDA regulated | No |
| Human subjects | Yes |
| IRB approval | [Pending — IRB name, institution] |
| DSMB | Yes |
Description
Brief summary
This pragmatic randomized trial tests whether matching chronic low back pain treatment to a patient's dominant psychological pain phenotype improves outcomes compared to guideline-concordant usual care. Patients are phenotyped at baseline using four validated instruments (PCS, FABQ, PSEQ, CSI). In the matched arm, treatment is selected to target the dominant mechanism (catastrophizing, fear-avoidance, low self-efficacy, or central sensitization). The usual care arm receives non-stratified guideline-concordant care. The primary outcome is pain interference at 12 weeks.
Detailed description
Chronic low back pain (cLBP) affects approximately 20% of adults worldwide and is the leading cause of disability globally OPENALEX W2791379829. Despite this burden, treatments are applied in a one-size-fits-all fashion, with no systematic attempt to match treatment type to the individual patient's dominant pain mechanism. The IMMPACT consensus group has published two sets of recommendations (Edwards et al. 2016, 2022) calling for phenotype-stratified treatment trials, yet no randomized controlled trial has tested this approach OPENALEX W2359535866 OPENALEX W4300003434.
MATCH-Pain will be the first RCT to prospectively test psychological mechanism-matched treatment for any chronic pain condition. Participants are randomized 1:1 to phenotype-matched treatment (n=75) or guideline-concordant usual care (n=75). The phenotyping battery takes ~15 minutes and uses exclusively validated, freely available instruments. All four treatments in the matched arm are evidence-based, protocolized, and group-delivered over 6 weeks. The trial uses the NIH Task Force case definition for chronic LBP OPENALEX W2089675869 and IMMPACT-recommended outcome domains.
Conditions & Keywords
- Chronic Low Back Pain
- Pain Catastrophizing
- Central Sensitization
- Fear-Avoidance
- Precision Medicine
- Stratified Care
- Pain Phenotyping
Design
| Field | Entry |
|---|
| Study type | Interventional |
| Primary purpose | Treatment |
| Allocation | Randomized |
| Interventional model | Parallel assignment |
| Masking | Single (Outcome assessor) |
| Number of arms | 2 |
Arms & Interventions
Arm 1: Phenotype-Matched Treatment (Experimental)
Treatment determined by dominant psychological phenotype:
- High catastrophizing (PCS ≥30): 6-week Empowered Relief program (single 2-hour class + 4 weekly group booster sessions; Darnall protocol) OPENALEX W4384932949
- High fear-avoidance (FABQ-PA ≥15): 6-week graded exposure in vivo (physiotherapist-delivered; Vlaeyen protocol) OPENALEX W2117118000
- Low self-efficacy (PSEQ ≤20): 6-week Chronic Disease Self-Management Program (Lorig/Stanford model; group-based)
- Central sensitization (CSI ≥40): 6-week pain neuroscience education + graded exercise therapy (Nijs protocol) OPENALEX W3152283701
Arm 2: Guideline-Concordant Usual Care (Active Comparator)
Non-stratified care per ACP/NICE guidelines for chronic LBP:
- Brief clinician education on staying active
- Written patient educational booklet ("The Back Book" or equivalent)
- Referral to physiotherapy (generic exercise program, up to 6 sessions)
- Analgesic medications per stepped approach as needed
- Phenotype data collected but NOT disclosed to clinician or patient
Eligibility
| Criterion | Detail |
|---|
| Age | 18–70 years |
| Sex | All |
| Accepts healthy volunteers | No |
Inclusion criteria
- Non-specific LBP ≥3 months duration, present on ≥ half of days in past 6 months (NIH Task Force definition) OPENALEX W2089675869
- Average pain intensity ≥4/10 on NRS in past week
- Scores above clinical threshold on ≥1 phenotyping instrument (PCS ≥30 OR FABQ-PA ≥15 OR PSEQ ≤20 OR CSI ≥40)
- Able to attend group sessions and complete questionnaires in English
- Willing to be randomized
Exclusion criteria
- Specific spinal pathology (fracture, malignancy, infection, cauda equina syndrome)
- Scheduled for spine surgery within 6 months
- Current participation in structured psychological therapy for pain
- Pregnancy
- Severe psychiatric disorder that precludes group participation (active psychosis, acute suicidality)
- Inability to provide informed consent
- Does not meet threshold on any phenotyping instrument (i.e., all 4 scores in non-clinical range)
Outcomes
Primary outcome measure
- BPI-SF interference subscale mean score at 12 weeks [Time frame: 12 weeks post-randomization]
Secondary outcome measures
- Pain intensity (NRS 0–10) [Time frame: 6, 12, 24 weeks]
- Oswestry Disability Index [Time frame: 12, 24 weeks]
- EQ-5D-5L health utility [Time frame: 12, 24 weeks]
- Patient Global Impression of Change (PGIC) [Time frame: 12 weeks]
- Treatment satisfaction (5-point Likert) [Time frame: 12 weeks]
- Change in dominant phenotype score [Time frame: 6, 12 weeks]
- 30% pain responder rate [Time frame: 12 weeks]
Enrollment
Target: 150 participants
Contacts & Locations
[To be completed with PI and site information]
III. NIH R21 Grant Application Framework
Funding Mechanism Rationale
The R21 (Exploratory/Developmental Research Grant) is the ideal vehicle because:
- MATCH-Pain is a first-in-kind proof-of-concept trial testing a novel paradigm (mechanism-matching) that has never been tested in any RCT
- Budget fits within the R21 cap ($275K direct costs over 2 years)
- Timeline aligns with the R21's 2-year project period
- No preliminary data required (but available from Darnall, Vlaeyen, Nijs published work)
- Suitable NIH ICs: NINDS (via HEAL initiative), NIAMS (musculoskeletal pain), or NCCIH (non-pharmacologic approaches)
Application Outline (PHS 398 / SF424 structure)
Title Page
Title: Psychological Mechanism-Matched Treatment Versus Usual Care for Chronic Low Back Pain: A Pragmatic Stratified Randomized Trial (MATCH-Pain)
FOA: PAR-XX-XXX (HEAL Initiative: Improving Treatment for Acute and Chronic Pain) or PA-XX-XXX (NCCIH: Clinical Trial Planning and Implementation)
Proposed duration: 24 months
Direct costs: Year 1: 137,500∣Year2:137,500 | Total: $275,000
Specific Aims (1 page)
Opening paragraph - the problem
Chronic low back pain (cLBP) is the world's leading cause of disability, yet treatments are applied without regard to the mechanisms sustaining an individual patient's pain. The IMMPACT group has twice recommended (2016, 2022) that pain clinical trials adopt phenotype-stratified treatment designs, yet no RCT has ever prospectively tested whether matching treatment type to a patient's dominant psychological pain mechanism improves outcomes beyond standard care OPENALEX W4300003434 OPENALEX W2359535866.
Middle paragraph - what we will do
MATCH-Pain will be the first randomized controlled trial to test psychological mechanism-matched treatment for chronic pain. We will phenotype 150 cLBP patients on four dimensions - catastrophizing (PCS), fear-avoidance (FABQ), self-efficacy (PSEQ), and central sensitization (CSI) - and randomize them 1:1 to mechanism-matched treatment or guideline-concordant usual care. This directly addresses the largest identified gap in pain research: the translation of phenotyping science into clinical trial design.
Specific Aims
Aim 1: Determine whether phenotype-matched treatment reduces pain interference (BPI-SF) at 12 weeks compared to guideline-concordant usual care in adults with cLBP.
- Hypothesis: Matched treatment will produce a clinically meaningful reduction in BPI-SF interference (≥1.25 points) versus usual care.
Aim 2: Evaluate the effect of phenotype-matching on secondary outcomes including pain intensity, disability, quality of life, and patient satisfaction at 12 and 24 weeks.
- Hypothesis: Matched treatment will show superiority across multiple IMMPACT-recommended outcome domains.
Aim 3 (Exploratory): Characterize phenotype-specific treatment response patterns and identify which phenotype-treatment matches yield the largest effects.
- Exploratory aim: Generate effect estimates for each phenotype subgroup to power a future definitive Phase III trial.
Closing paragraph - impact
If successful, MATCH-Pain will demonstrate that a 15-minute, free phenotyping battery can meaningfully improve cLBP outcomes - establishing the template for precision psychological pain medicine and directly answering a decade-long gap identified by IMMPACT, the Lancet LBP Series, and the NIH HEAL Initiative.
Significance (2-3 pages)
Section 1: The burden
cLBP affects >500 million people globally, is the #1 cause of years lived with disability (GBD 2015), and costs the US healthcare system >$100 billion annually OPENALEX W2791379829. Current treatments produce only modest average effects (NNT 4–7 for most interventions) OPENALEX W1955446149.
Section 2: The precision medicine gap
Cite the gap analysis from our prior brief:
- 7 of 28 high-impact pain papers explicitly call for phenotype-stratified treatment
- IMMPACT published consensus recommendations in 2016 and updated them in 2022 OPENALEX W2359535866 OPENALEX W4300003434
- A systematic search of ClinicalTrials.gov found zero registered trials using phenotype-matched treatment allocation for chronic pain
- The STarT Back trial (Hill et al. 2011) stratified by prognostic risk but not by mechanism — a critical conceptual distinction OPENALEX W3006578289
Section 3: Why psychological phenotyping is the right first axis
- Psychological variables (catastrophizing, fear-avoidance, self-efficacy) are the strongest modifiable predictors of treatment response in cLBP OPENALEX W2800915060
- All four instruments are validated, free, and completable in 15 minutes
- Each phenotype has a corresponding evidence-based targeted intervention with published treatment manuals
- No new technology, drug, or device required — maximizes translational potential
Section 4: How this advances the field
- First RCT to test mechanism-matching for any chronic pain condition
- Directly addresses the #1 recommendation from IMMPACT (2016, 2022)
- Aligns with NIH HEAL Initiative priority of improving non-opioid treatments
- Establishes the proof-of-concept and effect sizes needed to power a definitive multicenter Phase III trial
Innovation (0.5–1 page)
-
Novel trial design. First-ever mechanism-matched (not risk-stratified) treatment trial for chronic pain. Distinct from STarT Back (prognostic risk → treatment intensity) by testing whether treatment type selection based on mechanism improves outcomes.
-
Scalable phenotyping. The 4-instrument battery (PCS + FABQ + PSEQ + CSI) requires no equipment, no specialist training, and no cost — deployable in any clinic globally.
-
Pragmatic yet mechanistically informed. Bridges the gap between mechanistic pain science (which identifies phenotypes) and pragmatic trial design (which tests real-world clinical decisions).
-
Template for expansion. The matched-treatment design is modular — future trials can test additional phenotyping axes (QST, neuroimaging, genetics) using the same framework.
Approach (6–8 pages)
Section 1: Overview of study design (0.5 page)
Refer to CONSORT flow chart and SPIRIT schedule above.
Section 2: Participants and setting (1 page)
- Setting: [Academic pain center or 2–3 primary care/PT clinics]
- Case definition: NIH Task Force for cLBP OPENALEX W2089675869
- Inclusion/exclusion criteria as specified in ClinicalTrials.gov registration
- Recruitment strategy: electronic health record screening, provider referral, community flyers
- Expected recruitment rate: 15 patients/month (based on cLBP referral volumes of ~40–60/month at typical academic centers; 25–30% enrollment rate)
Section 3: Phenotyping procedure (1 page)
| Instrument | Construct | Items | Time | Threshold | Normative Reference |
|---|
| PCS (Sullivan et al. 1995) | Pain catastrophizing | 13 | 3 min | ≥30 (clinically relevant) | Sullivan et al. 1995 |
| FABQ (Waddell et al. 1993) | Fear-avoidance beliefs | 16 | 4 min | PA ≥15 (high fear) | Waddell et al. 1993 |
| PSEQ (Nicholas 2007) | Pain self-efficacy | 10 | 3 min | ≤20 (low efficacy) | Nicholas 2007 |
| CSI (Mayer et al. 2012) | Central sensitization | 25 | 5 min | ≥40 (probable CS) | Neblett et al. 2013 |
Dominance assignment: Each score is converted to a z-score relative to published normative means for chronic pain populations. The phenotype with the most extreme z-score (furthest from the non-clinical mean in the pathological direction) is designated dominant. Ties resolved by pre-specified hierarchy: PCS > FABQ > CSI > PSEQ (based on effect size of targeted intervention evidence).
Exclusion note: Patients scoring in the non-clinical range on ALL four instruments are excluded (criterion #7) — these patients likely have a predominantly nociceptive presentation where psychological matching is less relevant.
Section 4: Interventions (2 pages)
Matched Arm: Four Mechanism-Specific Protocols
A. High Catastrophizing → Empowered Relief (Darnall protocol)
- Format: Single 2-hour group class + 4 weekly 45-min group booster sessions
- Content: Cognitive restructuring of catastrophizing, skills training (relaxation response, cognitive diffusion, behavioral activation)
- Dosage: 5 sessions over 6 weeks
- Evidence: Darnall et al. 2014 (pilot), 2021 (RCT), 2023 (review) OPENALEX W2052950845 OPENALEX W4384932949
- Therapist: Licensed psychologist or trained pain counselor
B. High Fear-Avoidance → Graded Exposure In Vivo (Vlaeyen protocol)
- Format: 6 individual or small-group sessions (60 min each) over 6 weeks
- Content: Education about fear-avoidance model, hierarchical exposure to feared activities, behavioral experiments
- Evidence: Vlaeyen et al. Cochrane review; Yang et al. 2022 meta-analysis OPENALEX W2117118000 OPENALEX W4220821354
- Therapist: Physiotherapist trained in graded exposure
C. Low Self-Efficacy → Chronic Disease Self-Management Program (Lorig model)
- Format: 6 weekly 2.5-hour group sessions
- Content: Action planning, problem solving, communication skills, symptom management, exercise planning
- Evidence: Lorig et al. extensive RCT evidence; Cochrane review
- Therapist: Trained lay leaders or healthcare professionals (per Stanford model)
D. Central Sensitization → Pain Neuroscience Education + Graded Exercise (Nijs protocol)
- Format: 2 PNE sessions (60 min) + 4 supervised graded exercise sessions over 6 weeks
- Content: Reconceptualization of pain as neural sensitivity, graded aerobic and strengthening exercise, pacing education
- Evidence: Nijs et al. 2021 OPENALEX W3152283701; Malfliet et al. (multiple RCTs)
- Therapist: Physiotherapist trained in PNE
Usual Care Arm: Guideline-Concordant Standard Pathway
Per ACP (Qaseem et al. 2017) and NICE (NG59) recommendations:
- Brief clinician education on staying active and favorable prognosis
- Written educational booklet
- Referral to physiotherapy (generic exercise, up to 6 sessions)
- Analgesic medications per stepped approach (paracetamol → NSAIDs → weak opioids as needed)
- Phenotype results NOT shared with clinician or patient
- All treatments received documented in standardized log at each assessment
Section 5: Outcome assessment (0.5 page)
Refer to the SPIRIT schedule of assessments chart above. All patient-reported outcomes collected electronically via REDCap. Outcome assessors blinded to allocation. Automated REDCap reminders + research coordinator follow-up calls for retention.
Section 6: Statistical analysis (1.5 pages)
Refer to full SAP above (Section I of this document). Key elements:
- Primary: ANCOVA on BPI-SF interference at 12 weeks, adjusted for baseline and phenotype
- Secondary: Mixed-effects longitudinal model across all timepoints
- Exploratory: Arm × phenotype interaction; responder analysis; cost-effectiveness
- Missing data: MICE under MAR + MNAR sensitivity
Section 7: Sample size justification (0.5 page)
Reference the power calculations above. Key parameters:
- δ = 1.25 (exceeds BPI-SF MCID of 1.0) OPENALEX W4392763844
- σ = 2.5 (from published cLBP trials, e.g., Krebs et al. 2018 SPACE trial) OPENALEX W2790175340
- ρ = 0.50 (baseline-outcome correlation)
- α = 0.05, power = 0.80
- ANCOVA-adjusted n = 47 per arm; inflated to 75 per arm for 15% attrition and phenotype subgroup exploration
Section 8: Potential limitations and mitigation (0.5 page)
| Limitation | Mitigation |
|---|
| Phenotype overlap (multiple high scores) | Z-score dominance algorithm with pre-specified hierarchy; sensitivity analysis excluding mixed-phenotype patients |
| No patient/therapist blinding | Assessor blinding; PGIC and EQ-5D (patient-reported) less susceptible to bias; treatment expectancy measured at baseline |
| Usual care heterogeneity | Standardized treatment log; per-protocol sensitivity analysis |
| Generalizability (single site) | Pragmatic design; broad inclusion criteria; planned multicenter Phase III if successful |
| Underpowered for subgroup effects | Aim 3 is explicitly exploratory; effect estimates used to power Phase III |
Timeline & Milestones
| Month | Milestone |
|---|
| 1–2 | IRB approval; ClinicalTrials.gov registration; finalize treatment manuals |
| 2–3 | Therapist training and fidelity assessment; REDCap database build; pilot test procedures with n=5 |
| 3–12 | Rolling recruitment (target: 15/month) |
| 3–18 | Treatment delivery (rolling) |
| 6–21 | Follow-up data collection (rolling) |
| 12 | Interim safety review (DSMB) |
| 18 | Interim safety review (DSMB) |
| 21 | Last 12-week primary endpoint collected → primary completion |
| 22 | Database lock; unblinding |
| 22–23 | Statistical analysis |
| 23–24 | Manuscript drafting and submission |
Budget Justification (R21 — $275K direct over 2 years)
| Category | Year 1 | Year 2 | Total | Justification |
|---|
| PI (15% effort) | $22,500 | $22,500 | $45,000 | Overall scientific leadership |
| Co-I: Psychologist (10%) | $12,000 | $12,000 | $24,000 | Treatment protocol supervision, fidelity |
| Co-I: Biostatistician (10%) | $12,000 | $15,000 | $27,000 | SAP, analysis, reporting |
| Research coordinator (50%) | $25,000 | $25,000 | $50,000 | Recruitment, scheduling, data collection |
| Therapist — matched arm (50%) | $35,000 | $35,000 | $70,000 | Group treatment delivery (all 4 protocols) |
| Participant compensation | $10,000 | $8,500 | $18,500 | $25/visit × 4–5 visits × 150 participants |
| Training materials & manuals | $3,000 | $0 | $3,000 | Treatment fidelity materials |
| Supplies / printing / booklets | $2,000 | $1,500 | $3,500 | Usual care educational booklets, forms |
| Publication costs | $0 | $4,000 | $4,000 | Open-access fees |
| Indirect costs (estimated) | - | - | (separate per institutional rate) | |
| Total direct | $121,500 | $123,500 | $245,000 | Under R21 cap with margin |
Dissemination Plan & Publication Strategy
| Product | Target | Timeline |
|---|
| Protocol paper | Trials or BMJ Open | Month 4 |
| ClinicalTrials.gov results posting | ClinicalTrials.gov | Month 23 |
| Primary outcomes paper | Pain or JAMA Internal Medicine | Month 24 |
| Secondary outcomes / mechanisms paper | European Journal of Pain or J Pain | Month 26 |
| Cost-effectiveness analysis | Value in Health or Pain | Month 28 |
| IMMPACT commentary / editorial | Invited after primary results | Month 26+ |
| Phase III multicenter R01 application | NIH HEAL / NIAMS | Month 24 (based on MATCH-Pain results) |
Human Subjects
- Risks: Minimal. All interventions are non-invasive psychological/educational treatments used routinely in clinical practice. Potential risks include temporary emotional discomfort during exposure exercises (graded exposure arm) and inconvenience of study visits. No greater than standard clinical care.
- Benefits: Matched arm participants may experience improved pain outcomes. Usual care participants receive guideline-concordant care. All participants contribute to advancing precision pain medicine.
- Data safety: REDCap with institutional security; de-identified datasets for analysis; DSMB oversight every 6 months.
- Vulnerable populations: None specifically targeted. Standard protections for adults with chronic pain.
Summary
This package provides three complete, interlocking deliverables:
- Statistical Analysis Plan — Pre-specified ANCOVA primary analysis, mixed-effects longitudinal model, MICE imputation, Hochberg-adjusted secondary outcomes, and exploratory phenotype × treatment interaction testing
- ClinicalTrials.gov Protocol — All PRS fields populated, SPIRIT-compliant, ready for registration upon IRB approval
- NIH R21 Grant Framework — Specific Aims, Significance, Innovation, and Approach sections drafted; budget justified within R21 cap ($275K); timeline fits 24-month project period
The next steps would be:
- Finalize the PI and site details
- Submit to local IRB
- Adapt the R21 framework to the specific FOA you plan to target (I can help identify the best current HEAL or NCCIH announcement)
- Draft the biosketch, facilities, and equipment sections
Shall I proceed with any of these, or refine any section of the above?